bfcr4350a: a novel bispecific antibody in r/r myeloma therapy
Published 3 years ago • 93 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
2:17
the role of car t-cell therapy for treating myeloma in the era of bispecific antibodies
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
1:48
the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
3:24
novel agents for the management of r/r myeloma
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
2:38
approaching the treatment of patients with lbcl who relapse after bispecific antibodies
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
2:48
novel targets in multiple myeloma
-
1:59
the growing importance of celmods in the treatment of r/r multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
2:15
novel immunotherapies for the treatment of multiple myeloma
-
2:46
managing patients with high-risk myeloma